G1 Therapeutics
G1 Therapeutics[edit | edit source]
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and delivery of next-generation therapies that improve the lives of those affected by cancer. The company is headquartered in Research Triangle Park, North Carolina, and is known for its innovative approach to cancer treatment.
History[edit | edit source]
G1 Therapeutics was founded in 2008 as a spin-off from the University of North Carolina at Chapel Hill. The company was established to commercialize discoveries made in the laboratory of Dr. Norman Sharpless, who later became the director of the National Cancer Institute.
Research and Development[edit | edit source]
G1 Therapeutics is primarily focused on developing small molecule therapies that target the cell cycle to treat cancer. The company's lead product candidates are designed to protect bone marrow from damage caused by chemotherapy and to enhance the efficacy of cancer treatments.
Trilaciclib[edit | edit source]
Trilaciclib is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy. It is a CDK4/6 inhibitor that is administered intravenously prior to chemotherapy to protect hematopoietic stem cells and immune cells.
Rintodestrant[edit | edit source]
Rintodestrant is an oral selective estrogen receptor degrader (SERD) being developed for the treatment of hormone receptor-positive breast cancer. It is designed to degrade the estrogen receptor and inhibit the growth of cancer cells.
Clinical Trials[edit | edit source]
G1 Therapeutics has conducted several clinical trials to evaluate the safety and efficacy of its product candidates. These trials are conducted in collaboration with leading cancer research centers and involve patients with various types of cancer.
Partnerships and Collaborations[edit | edit source]
The company has established partnerships with several pharmaceutical companies and research institutions to advance its drug development programs. These collaborations are aimed at accelerating the clinical development and commercialization of G1 Therapeutics' therapies.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
